Cowen

Avantor® to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 28, 2023
Avantor, NYSE, Raymond James Financial, Webcast, AVTR, Raymond, Cowen

RADNOR, Pa., Feb. 28, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced that management will present at two upcoming investor conferences.

Key Points: 
  • RADNOR, Pa., Feb. 28, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced that management will present at two upcoming investor conferences.
  • Thomas Szlosek, Chief Financial Officer, will present at the Raymond James 44th Annual Institutional Investors conference in Orlando, Fla. on Monday, March 6 at 1:40 p.m. Eastern Standard Time.
  • Michael Stubblefield, President & CEO, will participate in a fireside chat at Cowen's 43rd Annual Health Care conference in Boston, Mass.
  • To hear live audio webcasts of these upcoming sessions, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com .

Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference

Retrieved on: 
Tuesday, February 28, 2023
Conference, Cowen, Patient, Pharmaceutical industry, Self storage

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m.

Key Points: 
  • DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m.
  • ET.
  • An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

Hologic to Webcast Presentation at the Cowen 43rd Annual Health Care Conference

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Surgery, Medical Devices, Health, Health Technology, Conference, HOLX, Hologic, Research, Cowen

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7 at 9:10 a.m. Eastern Time (E.T.)

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7 at 9:10 a.m. Eastern Time (E.T.)
  • Cowen’s 43rd Annual Health Care Conference is taking place March 6 - 8, 2023, at the Boston Marriott Copley Place in Boston, MA.
  • The conference incorporates presentations, fireside chats and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.
  • The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com .

Tvardi Therapeutics to Participate at the Cowen 43rd Annual Health Care Conference

Retrieved on: 
Tuesday, February 28, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Conference, STAT3, Therapy, Cowen, Pharmaceutical industry, Hotel

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the company has been invited to participate at the Cowen 43rd Annual Health Care Conference.

Key Points: 
  • Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the company has been invited to participate at the Cowen 43rd Annual Health Care Conference.
  • The management team will hold one-on-one meetings on March 8, 2023, to review emerging clinical data.
  • Cowen’s 43rd Annual Health Care Conference is taking place March 6 - 8, 2023, at the Boston Marriott Copley Place in Boston, MA.
  • The conference incorporates presentations, fireside chats and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.

AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference

Retrieved on: 
Monday, February 27, 2023
Conference, Therapy, SAN, Webcast, Cowen, Pharmaceutical industry, Broadcasting

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics today announced that Dan Faga, interim president and chief executive officer, will present at the Cowen and Company 43rd Annual Health Care Conference on Monday, March 6, 2023, at 2:50 p.m.

Key Points: 
  • SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics today announced that Dan Faga, interim president and chief executive officer, will present at the Cowen and Company 43rd Annual Health Care Conference on Monday, March 6, 2023, at 2:50 p.m.
  • ET / 11:50 a.m. PT.
  • A live audio webcast of the presentation will be available on the investor section of the AnaptysBio website at https://ir.anaptysbio.com/events .
  • A replay of the webcast will be available for at least 30 days following the event.

Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, February 27, 2023
General Health, Pharmaceutical, Health, Other Health, Conference, Ironwood Pharmaceuticals, Medication, Software, Barclays, Cowen, Pharmaceutical industry, Hotel, Ironwood

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences:

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences:
    Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m.
  • ET at the Boston Marriott Copley Place
    Barclays Global Healthcare Conference on Tuesday, March 14, 2023 at 8:00 a.m.
  • To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start times to ensure adequate time for any software downloads that may be required.
  • A replay of the webcasts will be available on Ironwood’s website for 14 days following the conferences.

Xencor Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, ENPP3, Pembrolizumab, CD28, Caris, Cancer, RCC, Immune system, Cowen, Psoriasis, Laboratory, IND, CLDN6, Investment, Patient, Biology, R, Janssen, Neoplasm, CD20, Renal cell carcinoma, Bispecific monoclonal antibody, Therapeutic index, Sale, Antibody, CD3, Cytokine, Protein engineering, Novartis, Kidney cancer, Vir, G&A, Prostate, Atopic dermatitis, Vaccine, Cryptocurrency, Online shopping, Barclays, Regulatory T cell, Astellas Pharma, MorphoSys, Alexion

Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022

Key Points: 
  • Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022
    Cash, cash equivalents, receivables and marketable debt securities totaled $613.5 million as of December 31, 2022, compared to $664.1 million on December 31, 2021.
  • Total revenue for the fourth quarter ended December 31, 2022 was $21.6 million compared to $154.0 million for the same period in 2021.
  • General and administrative (G&A) expenses for the fourth quarter ended December 31, 2022 were $12.8 million compared to $11.4 million for the same period in 2021.
  • ET (1:30 p.m. PT) to discuss the full year 2022 financial results and provide a corporate update.

Median Technologies to Participate in the Cowen’s 43rd Annual Health Care Conference

Retrieved on: 
Thursday, February 23, 2023
Radiology, Biotechnology, Oncology, Health, Artificial Intelligence, Medical Devices, Technology, Other Technology, Cowen Inc., Research, Conference, Cowen, Financial services

Median Technologies (Paris:ALMDT), will be participating in the Cowen’s 43rd Annual Health Care Conference, taking place on March 6 – 8 ,2023, at the Boston Marriott Copley Place in Boston, MA, USA.

Key Points: 
  • Median Technologies (Paris:ALMDT), will be participating in the Cowen’s 43rd Annual Health Care Conference, taking place on March 6 – 8 ,2023, at the Boston Marriott Copley Place in Boston, MA, USA.
  • The live presentation will be available here and the replay will be posted on Median Technologies’ website, Investors section.
  • Cowen’s 43rd Annual Health Care Conference is taking place March 6 - 8, 2023, at the Boston Marriott Copley Place in Boston, MA.
  • The conference incorporates presentations, fireside chats and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.

Biotech and Genomics Expert, Dr. Lin Yu, Joins GATC Health's Board of Directors

Retrieved on: 
Thursday, February 23, 2023
GATC, DNA, Artificial intelligence, Research fellow, Research, Drug development, Cowen, Acquisition, Drug discovery, KKR, Growth, Doctor of Philosophy, Therapy, Chemical engineering, DRI Capital, Cooper Union, Columbia University, Art, Securities research, Medical device, Medtech, Science

IRVINE, Calif., Feb. 23, 2023 /PRNewswire/ -- GATC Health Corp, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), welcomes Lin Yu, Ph.D., to its Board of Directors. Dr. Yu brings a powerful combination of academic acumen and financial experience in medtech and life sciences with BTIG Healthcare, KKR, Cowen & Co. and, most recently as Managing Director at Oppenheimer Healthcare Investment Banking to GATC's board.

Key Points: 
  • IRVINE, Calif., Feb. 23, 2023 /PRNewswire/ -- GATC Health Corp, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), welcomes Lin Yu, Ph.D., to its Board of Directors.
  • Dr. Yu brings investment banking, gene sequencing technology and drug development expertise to GATC.
  • "Dr. Yu has a very specific mandate as director with GATC," noted the company's president, Jeff Moses.
  • We are extremely pleased to welcome him to our team and look forward to his contributions as a director on our board."

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 23, 2023
Clinical trial, Synovial sarcoma, Finance, Therapy, PD, BRD9, BRAF V600, Disease, Research, Investigational New Drug, Lung cancer, Colorectal cancer, IND, BRAF, Controlled Impact Demonstration, Patient, R, Research and development, Ongo, CRC, NSCLC, Conference, AACR, Biogen, Administration, CCCC, PK, Dexamethasone, Melanoma, Cowen, Pharmaceutical industry, Fine chemical, Cryptocurrency, Calico

WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported business highlights and financial results for the year ended December 31, 2022.

Key Points: 
  • CFT8634: CFT8634 is an oral degrader of BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.
  • Dosed First Patient in Phase 1/2 Clinical Trial: In January 2023, dosed the first patient in the CFT1946 Phase 1/2 clinical trial.
  • The increase in G&A expense was primarily attributable to the full-year 2022 impact of the build-out of our general and administrative team to support business growth.
  • Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of December 31, 2022 was $337.1 million, compared to $451.5 million as of December 31, 2021.